fidarestat has been researched along with losartan in 1 studies
| Studies (fidarestat) | Trials (fidarestat) | Recent Studies (post-2010) (fidarestat) | Studies (losartan) | Trials (losartan) | Recent Studies (post-2010) (losartan) |
|---|---|---|---|---|---|
| 97 | 3 | 33 | 7,231 | 1,245 | 2,118 |
| Protein | Taxonomy | fidarestat (IC50) | losartan (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 9.01 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2.882 | |
| Angiotensin-converting enzyme | Homo sapiens (human) | 0.019 | |
| Atrial natriuretic peptide receptor 3 | Homo sapiens (human) | 0.0018 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.019 | |
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0247 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0234 | |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | 0.0032 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.047 | |
| Type-1 angiotensin II receptor | Oryctolagus cuniculus (rabbit) | 0.025 | |
| Type-2 angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0118 | |
| Type-2 angiotensin II receptor | Homo sapiens (human) | 0.019 | |
| Platelet glycoprotein VI | Homo sapiens (human) | 4 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.1481 | |
| Type-1 angiotensin II receptor | Cavia porcellus (domestic guinea pig) | 0.018 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.2884 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, R; Chung, CH; Hong, SW; Kim, BH; Kim, JH; Kim, SH; Koh, JH; Lee, EY; Lee, MY; Nam, SM; Sung, JK; Yoo, JH | 1 |
1 other study(ies) available for fidarestat and losartan
| Article | Year |
|---|---|
Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats.
Topics: Aldehyde Reductase; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Imidazolidines; Kidney; Losartan; Male; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor A | 2010 |